EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management

Michael Pazianas iD, Paul Dennis Miller iD

Journal of Bone Metabolism · 2020 · 27 (1) · 1

DOI: 10.11005/jbm.2020.27.1.1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Bone Metabolism, 2020. Verfasst von Michael Pazianas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic Kidney disease (CKD) disturbs mineral homeostasis leading to mineral and bone disorders (MBD). Serum calcium and phosphate (Pi) remain normal until the late stages of CKD at the expense of elevate fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, followed by reduced 1,25-dihydroxy-vitamin D (1,25[OH]2D) and finally elevated parathyroid hormone (PTH). Pi retention is thought to be the initial cause of CKD-MBD. The management of MBD is a huge clinical challenge because the effectiveness of current therapeutic regimens to prevent and treat MBD is limited. An intermittent regimen of PTH, when administered at the early stages of CKD, through its phosphaturic action, could prevent FGF-23 increases, the drop of 1,25(OH)2D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD.

Schlagwörter

Stichwörter der Autor:innen

CalciumChronic kidney disease-mineral and bone disorderFibroblast growth factor-23Parathyroid hormonePhosphate

Autor:innen und Institutionen

  • Institute of Musculoskeletal Sciences, Oxford University, Oxford, United Kingdom.
  • University of Colorado Health Sciences Center, Denver, CO, USA.
  • Colorado Center for Bone Research, Golden, CO, USA.

ORCID-Profile: Michael Pazianas, Paul Dennis Miller

Zitieren

APA

Pazianas, M., & Miller, P. D. (2020). Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management. Journal of Bone Metabolism, 27(1), 1. https://doi.org/10.11005/jbm.2020.27.1.1

Vancouver

Pazianas M, Miller PD. Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management. Journal of Bone Metabolism. 2020;27(1):1. doi:10.11005/jbm.2020.27.1.1

BibTeX
@article{Pazianas2020,
  author = {Pazianas, Michael and Miller, Paul Dennis},
  title = {Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management},
  journal = {Journal of Bone Metabolism},
  year = {2020},
  volume = {27},
  number = {1},
  pages = {1},
  doi = {10.11005/jbm.2020.27.1.1}
}
Kostenlos starten →